Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7566410 | 0.99 | CMA1 (0.57) | CMA1CTRC | |
| SCHEMBL6708761 | 0.90 | CMA1 (0.46) | CMA1CTRC | |
| SCHEMBL7961182 | 0.88 | CMA1 (0.46) | CMA1CTRC | |
| SCHEMBL4350497 | 0.88 | CMA1 (0.44) | CMA1CTRC | |
| SCHEMBL31419970 | 0.88 | CMA1 (0.44) | CMA1CTRC | |
| SCHEMBL6710145 | 0.88 | ELANE (0.47) | CMA1CTRC | |
| SCHEMBL7951052 | 0.87 | CTRC (0.47) | CMA1CTRC | |
| SCHEMBL7951397 | 0.86 | CMA1 (0.45) | CMA1CTRC | |
| SCHEMBL7950471 | 0.86 | CMA1 (0.45) | CMA1CTRC | |
| SCHEMBL7960975 | 0.86 | CMA1 (0.43) | CMA1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6271238-B1 | USEFUL IN TREATING AND PREVENTING DISEASES INVOLVING CHYMOTRYPSIN TYPE PROTEASES WHICH ARE RELATED TO ASTHMA, ALLERGY, INFLAMMATIONS, RHEUMATISM, HYPERTENSION, HEART FAILURE, MYOCARDIAL INFARCTION, AND CARDIAC HYPERTROPHY | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | claimed |
| EP-0936216-A1 | NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-08-18 | — | — | EP | claimed |
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2004-01-29 | — | — | US | disclosed |
| US-6271238-B1 | USEFUL IN TREATING AND PREVENTING DISEASES INVOLVING CHYMOTRYPSIN TYPE PROTEASES WHICH ARE RELATED TO ASTHMA, ALLERGY, INFLAMMATIONS, RHEUMATISM, HYPERTENSION, HEART FAILURE, MYOCARDIAL INFARCTION, AND CARDIAC HYPERTROPHY | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-08-07 | — | — | US | disclosed |
| EP-0936216-A1 | NOVEL ACETAMIDE DERIVATIVES AND PROTEASE INHIBITORS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1999-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | CMA1, ACE, AGTR1 | CMA1 1/4885CTRC 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.